Table III.

Distribution of PRR4 gene expression and its association with clinicopathological characteristics of the patients.

	PRR4 gene expression, n (%)
Clinicopathological parameter	Decreased	No change	Increased	P-valuea
Clinical stage				0.903
Early stage (I+II)	7 (7.8)	0 (0)	3 (3.3)
Advanced stage (III+IV)	57 (63.3)	1 (1.1)	20 (22.2)
Unknown	1 (1.1)	0 (0)	1 (1.1)	NT
Histology				NT
SCC	64 (71.1)	1 (1.1)	21 (23.3)
Non-SCC	0 (0)	0 (0)	2 (2.2)
Unknown	1 (1.1)	0 (0)	1 (1.1)
Sex				0.951
Female	2 (2.2)	0 (0)	1 (1.1)
Male	63 (70)	1 (1.1)	23 (25.6)
Age				0.5
≤50	8 (8.9)	0 (0)	5 (5.6)
>50	57 (63.3)	1 (1.1)	18 (20)
Unknown	0 (0)	0 (0)	1 (1.1)	NT
Histological grade				0.327
Low grade (1+2)	31 (34.4)	0 (0)	8 (8.9)
High grade (3+4)	30 (33.3)	1 (1.1)	14 (15.6)
Unknown	4 (4.4)	0 (0)	2 (2.2)	NT
Smoking				0.815
Smoker	53 (58.9)	1 (1.1)	20 (22.2)
Non-smoker	11 (12.2)	0 (0)	3 (3.3)
Unknown	1 (1.1)	0 (0)	1 (1.1)	NT
Total	65 (72.2)	1 (1.1)	24 (26.7)	0.001

^aStatistical analyses were performed using the Pearson's χ² test. NT, not tested; SCC, squamous cell carcinoma; PRR4, proline-rich 4.